drugset / Trial / NCT01895491
Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to evaluate the safety of VM206RY in subjects with expression of HER2 in breast cancer.
Timeline
- Start
- 2011-03
- Primary completion
- 2013-07
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VM206Ad | Unknown | 3e+09 unknown | Intramuscular |
| Subject | VM206DNA | Unknown | 6 mg | Intramuscular |
| Subject | VM206DNA | Unknown | 12 mg | Intramuscular |
| Subject | VM206DNA | Unknown | 24 mg | Intramuscular |